Merck - Top 13 Advertising Budgets
Company: Merck 
2007 Ad Spending: $751.8 million
2006 Ad Spending: $1.02 billion
Breakdown:
- Magazines: $125.4 million
- Newspaper: $13.6 million
- Outdoor: N/A
- TV: $212.2 million
- Radio: $300,000
- Internet: $24.5 million
Where Merck is spending money: The company slashed its ad spending by about $250 million in 2007. But it still managed to increase media support for the cholesterol drug Zetia to $105.9 million from $93.64 million, a 13 percent hike. The company's biggest ad push was for Gardasil--its vaccine for human papillomavirus, which causes cervical cancer and genital warts. Merck allocated $101.4 million to the shot, up 137 percent from the previous year's $42,740.
That's one reason Gardasil led a big increase in Merck's vaccine division's revenue. The HPV vaccine brought in $1.5 billion worldwide, up from $234.8 million in 2006, when the shot was first approved in the U.S.
Global sales of Zetia grew by 25 percent to $2.4 billion. But Merck doesn't get all that revenue; the drug is part of a joint venture with Schering-Plough, along with a sister product, Vytorin, that combines Zetia with the Merck statin Zocor. The entire Merck/Schering-Plough joint venture added $1.83 billion to Merck's revenues, according to financial statements.
Where Merck isn't spending money: Merck almost got out of the image-advertising business, slashing its corporate brand budget by 78 percent, from $172 million to $38.6 million. And the company cut back its spending on the allergy and asthma med Singulair by 27.5 percent, to $82 million. Osteoporosis treatment Fosamax also saw the knife, with a 49 percent cut to $32.7 million. Singular still managed $4.3 billion in global sales, up from $3.6 billion the previous year. Fosamax, on the other hand, saw its sales drop slightly to $3.05 billion.
Comments
Gardasil does not cause cervical cancer or genital warts..... (it prevents them)
Sorry, but their have been cases of cervical warts and cancer in young girls who received the gardahell shot. It is an unproven fast-tracked vaccine that has injured 1000's. How many girls will have to die before it's pulled?
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: